Biontech and oncoc4 announce strategic collaboration to co-develop and commercialize novel checkpoint antibody in multiple solid tumor indications

Mainz, germany and rockville, maryland, usa, march 20, 2023 – biontech se (nasdaq: bntx, “biontech”) and oncoc4, inc. (“oncoc4”), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel biologicals for cancer treatment, today announced that they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize oncoc4's next-generation anti-ctla-4 monoclonal antibody candidate, onc-392, as monotherapy or combination therapy in various cancer indications. the transaction is expected to close in the first half of 2023, subject to customary closing conditions and regulatory clearances.
BNTX Ratings Summary
BNTX Quant Ranking